Publications by authors named "Kate Manos"

Claim this Profile
T
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.
Eliza A Hawkes, Jodie B Palmer, Richard Khor, Sze Ting Lee, Melinda Burgess, Kate Manos

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.
Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoff Chong, Kate Manos

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.
Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, Alison Griffin, Rakin Chowdhury, Kate Manos

Blood Neoplasia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
Kate Manos, Leonid Churilov, Andrew Grigg, Pietro Di Ciaccio, Jonathan Wong

Br J Haematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
Masa Lasica, Mary A Anderson, Alex Boussioutas, Gareth P Gregory, Nada Hamad, Kate Manos

Intern Med J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Briony Shaw, Eliza Chung, Cameron Wellard, Edward Yoo, Rory Bennett, Kate Manos

EJHaem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Pietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, Alina S Gerrie, Catherine Burton, Kate Manos

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Suzanne O Arulogun, Duncan Brian, Harshita Goradia, Aaron Cooney, Tobias Menne, Kate Manos

Am J Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith

Leukemia· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Matthew R Wilson, Toby A Eyre, Amy A Kirkwood, Nicole Wong Doo, Carole Soussain, Kate Manos

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safe administration of obinutuzumab to rituximab-intolerant patients.
Kate Manos, Andrew Grigg

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of non-myeloablative allogeneic stem cell transplant in older patients with acute myeloid leukaemia in first remission.
Phillip C Nguyen, Kate Manos, Chun Y Fong, Anthony P Schwarer, Ing S Tiong

Intern Med J· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Nicolas Martinez-Calle, Amy A Kirkwood, Maxine Lamb, Alex Smith, Jahanzaib Khwaja, Kate Manos

Adv Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years.
Zoe Loh, Ross Salvaris, Geoffrey Chong, Leonid Churilov, Kate Manos

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myeloid somatic mutation panel testing in myeloproliferative neoplasms.
David M Ross, Candice Thomson, Nada Hamad, Steven W Lane, Kate Manos

Pathology· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Katharine L Lewis, Collin K Chin, Kate Manos, John Casey, Nada Hamad

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Manos

Hematol Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis